Initial testing (stage 1) of the anti‐microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 1545-5009, Iss. 11, 2015-11 ,pp. : 1897-1905

John Wiley & Sons Inc

Access to resources Recommend Favorite

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 6, 2015-06 ,pp. : 1106-1109

John Wiley & Sons Inc

Access to resources Recommend Favorite

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ‐26481585), by the Pediatric Preclinical Testing Program

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 61, Iss. 2, 2014-02 ,pp. : 245-252

John Wiley & Sons Inc

Access to resources Recommend Favorite

Initial testing (Stage 1) of TAK‐701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 61, Iss. 2, 2014-02 ,pp. : 380-382

John Wiley & Sons Inc

Access to resources Recommend Favorite

Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin‐bound (nab) paclitaxel (Abraxane®) by the Pediatric Preclinical Testing Program (PPTP)

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 7, 2015-07 ,pp. : 1214-1221

John Wiley & Sons Inc

Access to resources Recommend Favorite